Cargando…
Delivery strategies for macromolecular drugs in cancer therapy
With the development of biotherapy, biomacromolecular drugs have gained tremendous attention recently, especially in drug development field due to the sophisticated functions in vivo. Over the past few years, a motley variety of drug delivery strategies have been developed for biomacromolecular drug...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332661/ https://www.ncbi.nlm.nih.gov/pubmed/32642406 http://dx.doi.org/10.1016/j.apsb.2020.01.009 |
_version_ | 1783553566492852224 |
---|---|
author | Guo, Qin Jiang, Chen |
author_facet | Guo, Qin Jiang, Chen |
author_sort | Guo, Qin |
collection | PubMed |
description | With the development of biotherapy, biomacromolecular drugs have gained tremendous attention recently, especially in drug development field due to the sophisticated functions in vivo. Over the past few years, a motley variety of drug delivery strategies have been developed for biomacromolecular drugs to overcome the difficulties in the druggability, e.g., the instability and easily restricted by physiologic barriers. The application of novel delivery systems to deliver biomacromolecular drugs can usually prolong the half-life, increase the bioavailability, or improve patient compliance, which greatly improves the efficacy and potentiality for clinical use of biomacromolecular drugs. In this review, recent studies regarding the drug delivery strategies for macromolecular drugs in cancer therapy are summarized, mainly drawing on the development over the last five years. |
format | Online Article Text |
id | pubmed-7332661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-73326612020-07-07 Delivery strategies for macromolecular drugs in cancer therapy Guo, Qin Jiang, Chen Acta Pharm Sin B Review With the development of biotherapy, biomacromolecular drugs have gained tremendous attention recently, especially in drug development field due to the sophisticated functions in vivo. Over the past few years, a motley variety of drug delivery strategies have been developed for biomacromolecular drugs to overcome the difficulties in the druggability, e.g., the instability and easily restricted by physiologic barriers. The application of novel delivery systems to deliver biomacromolecular drugs can usually prolong the half-life, increase the bioavailability, or improve patient compliance, which greatly improves the efficacy and potentiality for clinical use of biomacromolecular drugs. In this review, recent studies regarding the drug delivery strategies for macromolecular drugs in cancer therapy are summarized, mainly drawing on the development over the last five years. Elsevier 2020-06 2020-01-26 /pmc/articles/PMC7332661/ /pubmed/32642406 http://dx.doi.org/10.1016/j.apsb.2020.01.009 Text en © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Guo, Qin Jiang, Chen Delivery strategies for macromolecular drugs in cancer therapy |
title | Delivery strategies for macromolecular drugs in cancer therapy |
title_full | Delivery strategies for macromolecular drugs in cancer therapy |
title_fullStr | Delivery strategies for macromolecular drugs in cancer therapy |
title_full_unstemmed | Delivery strategies for macromolecular drugs in cancer therapy |
title_short | Delivery strategies for macromolecular drugs in cancer therapy |
title_sort | delivery strategies for macromolecular drugs in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332661/ https://www.ncbi.nlm.nih.gov/pubmed/32642406 http://dx.doi.org/10.1016/j.apsb.2020.01.009 |
work_keys_str_mv | AT guoqin deliverystrategiesformacromoleculardrugsincancertherapy AT jiangchen deliverystrategiesformacromoleculardrugsincancertherapy |